Please amend Claims 2, 5-8 and 13-16 as follows:

2. (Amended) The pharmacological agent of claim 17 wherein the therapeutically effective amount of *Uncaria tomentosa* comprises a dosage in the range of from about 10 to 1,000 mg/kg of body weight of the patient.

5. (Amended) The pharmacological agent of claim 18 wherein said amyloid disease for treatment is Alzheimer's Disease.

6. (Amended) The pharmaceutical agent of claim 17 further comprising a pharmaceutically acceptable carrier, diluent or excipient.

7. (Amended) The pharmaceutical agent of claim 17 wherein the therapeutically effective amount of plant matter has an amyloid inhibitory activity or efficacy greater than 50%.

8. (Amended) A method of treating an amyloid disease in a patient, comprising the step of administering to the patient a therapeutically effective amount of plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in combination with a therapeutically effective amount of one or more substances selected from the group consisting of Gingko Biloba, Ginseng, Gotu Kola, Echinacea, Vitamin E, Selenium, Niacin or nicotinate, Folic acid, Vitamin B12 or cobalamin, and Choline.

13. (Amended) The pharmacological agent of claim 19 wherein the therapeutically effective amount of *Uncaria tomentosa* comprises a dosage in the range of from about 10 to 100 mg/kg of body weight of the patient.

14. (Amended) The pharmacological agent of claim 19 wherein said amyloid disease for treatment is Type II Diabetes.

15. (Amended) The pharmaceutical agent of claim 19 wherein the therapeutically effective amount of plant matter has an amyloid inhibitory activity or efficacy greater than 50%.

16. (Amended) A method of treating an amyloid disease in a patient, comprising the step of administering to the patient a therapeutically effective amount of plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in combination with a therapeutically effective amount of one or more substances selected from the group consisting of Bilberry, Dong Quai, Aloe Vera, Chromium Polynicotinate, Selenium, Vitamin B12 or cobalamin, Folic acid, Biotin, and Thiamine ~~HCl~~ or vitamin B1.

Please add new claim 17-19 as follows:

17. (New) A pharmacological agent comprising a therapeutically effective amount of plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in combination with a therapeutically effective amount of one or more substances selected from the group consisting of Gingko Biloba, Ginseng, Gotu Kola, Vitamin E, Selenium, Niacin or nicotinate, Folic acid, Vitamin B12, and Choline, the plant matter and substance and the therapeutic amount of the plant matter and substance selected for efficacy in treating an amyloid disease in a patient.

18. (New) The pharmaceutical agent of claim 17 wherein an amyloid associated with the amyloid disease for treatment is selected from a group of amyloids consisting of:

a) the amyloid associated with Alzheimer's disease, Down's syndrome or hereditary cerebral hemorrhage with amyloidosis of the Dutch type, wherein the amyloid is referred to as beta-amyloid protein or Aß,

b) the amyloid associated with chronic inflammation, various forms of malignancy or Familial Mediterranean Fever, wherein the amyloid is referred to as AA amyloid or inflammation-associated amyloidosis,

c) the amyloid associated with multiple myeloma or other B-cell dyscrasias, wherein the amyloid is referred to as AL amyloid,

d) the amyloid associated with type II diabetes wherein the amyloid is referred to as amylin or islet amyloid,

e) the amyloid associated with the prion diseases including Creutzfeldt-Jakob disease, Gerstmann-Straussler syndrome, kuru and animal scrapie, wherein the amyloid is referred to as PrP amyloid,

f) the amyloid associated with long-term hemodialysis or carpal tunnel syndrome, wherein the amyloid is referred to as beta$_2$-microglobulin amyloid,

g) the amyloid associated with senile cardiac amyloid or Familial Amyloidotic Polyneuropathy, wherein the amyloid is referred to as transthyretin or prealbumin, and

h) the amyloid associated with endocrine tumors such as medullary carcinoma of the thyroid wherein the amyloid is referred to as variants of procalcitonin.

19. (New) A pharmacological agent comprising a therapeutically effective amount of plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in combination with a therapeutically effective amount of one or more substances selected from the group consisting of Dong Quai, Chromium Polynicotinate, Selenium, Vitamin B12 or cobalamin, Folic acid, Biotin, and Thiamine HCl, or vitamin B1, the plant matter and substance and the therapeutic amount of the plant matter and substance selected for efficacy in treating an amyloid disease in a patient.

REMARKS

Claims 1 - 16 are pending the application; Claims 1, 4-7, 12, 14 and 15 stand rejected under 35 USC §102, Claims 2, 3 and 13 have been indicated as allowable if rewritten to include the limitations of the base and intervening claims, and Claims 8-11 and 16 stand allowed. By this Amendment Claims 1, 4 and 12 have been canceled and replaced with new claim 17-19 respectively. Claims 2, 5-8 and 13-16 have been amended. These amendments and new claims add no new matter to the application.